A Trojan horse PRINT particle composition was developed that incorporates a reductively labile cross-linker to achieve activated release of doxorubicin in vitro. Particles of discrete size and shape (cube side length = 2 micron) containing 30 wt % of a disulfide-based cross-linker and 2 wt % doxorubicin were synthesized. This PRINT composition was shown to release doxorubicin in response to a reducing environment as measured by flow cytometry and was found to be highly proficient at killing HeLa cells in vitro.
No takes yet. Share an insight, caveat, or question.
Petros et al. (2008) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: